Interactions between cardiology and oncology drugs in precision cardio-oncology

摘要

Approximately 17 million cancer survivors compose 5% of the American population [1,2]. Advances in improved treatment approaches have led to an increase in survivorship and consequently, recognition of an association between cancer treatments and the development of cardiovascular complications. In addition, as the population becomes older, comorbid cardiovascular risk factors are more prevalent and compound the risk of developing cancer treatment-related cardiovascular toxicity [3]. Cardio-oncology has emerged as a new subspecialty of medicine that provides a multidisciplinary approach, bringing together oncologists, cardiologists, and allied healthcare providers who are tasked with optimizing the cardiovascular health of patients exposed to potentially cardiotoxic cancer therapy [3]. This field has emerged in